Nokta, M <br/><br/>
Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea.  [electronic resource] 

 -  AIDS research and human retroviruses  Dec 1997 
 - 1633-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0889-2229 
<br/><br/><label>Standard No.: </label>10.1089/aid.1997.13.1633  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-HIV Agents--therapeutic use<br/>Antigens, CD--metabolism<br/>CD4 Lymphocyte Count<br/>Didanosine--therapeutic use<br/>Drug Therapy, Combination<br/>Female<br/>HIV Infections--drug therapy<br/>Humans<br/>Hydroxyurea--therapeutic use<br/>Kinetics<br/>Male<br/>Middle Aged<br/>Receptors, Tumor Necrosis Factor--metabolism<br/>Receptors, Tumor Necrosis Factor, Type II<br/>Reverse Transcriptase Inhibitors--therapeutic use<br/>Solubility<br/>Stavudine--therapeutic use<br/>Tumor Necrosis Factor-alpha--metabolism<br/>Viremia